Joshua Hill, MD
Dr. Josh Hill is an Associate Professor at the Fred Hutchinson Cancer Center and the University of Washington (UW) in the Vaccine and Infectious Disease Division. His NIH-funded research program is focused on studies to improve preventive and treatment strategies for viral and other infections in immunocompromised patients.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AllovirTopic:Transplant ID expertiseDate added:05/07/2024Date updated:05/07/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Century TherapeuticsTopic:CAR-T cell therapy and infectionsDate added:05/07/2024Date updated:05/07/2024Relationship end date:10/31/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:CSL BehringTopic:CAR-T cell therapy and infectionsDate added:05/07/2024Date updated:05/07/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:EversanaTopic:Delphi panel for SARS-CoV-2 testing in immunocompromised patientsDate added:05/07/2024Date updated:05/07/2024Relationship end date:02/28/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GeoVaxTopic:ID protocol developmentDate added:05/07/2024Date updated:05/07/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GileadTopic:ID protocol developmentDate added:05/07/2024Date updated:05/07/2024Relationship end date:11/15/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GileadTopic:CAR-T cell therapy and infectionsDate added:05/07/2024Date updated:05/07/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GrifolsTopic:CAR-T cell therapy and infectionsDate added:05/07/2024Date updated:05/07/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:KariusTopic:ID diagnosticsDate added:05/07/2024Date updated:05/07/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:ModernaTopic:Vaccine trail DSMBDate added:05/07/2024Date updated:05/07/2024Relationship end date:01/05/2024